UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002041
Receipt number R000002486
Scientific Title A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)
Date of disclosure of the study information 2009/06/03
Last modified on 2015/04/11 16:14:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)

Acronym

A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)

Scientific Title

A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)

Scientific Title:Acronym

A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)

Region

Japan


Condition

Condition

advanced or recurrent esophagogastric carcinoma

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To estimate the maximum tolerated dose and the recommended dose of docetaxel combined with 5-fluorouracil for previously treated advanced or recurrent esophagogastric carcinoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

To estimate the maximum tolerated dose and the recommended dose

Key secondary outcomes

safety
efficacy


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

docetaxel and 5-fluorouracil

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Histologically confirmed esophageal or gastric carcinoma.
2. measurable or evaluable lesion
3. this chemotherapy is second or third line
4. No previous use of Taxan
5. Performance Status:0-2(ECOG)
6. Patients of age =>20 at the registration
7. Life expectancy more than 12 weeks
8. Sufficient organ functions within two weeks before registration
1) leukocytes =>3,000/mm3
2) neutrocytes =>1,500/mm3
3) platelets =>100,000/mm3
4) hemoglobin =>8.0g/dl
5) AST(GOT)/ALT(GPT) <=100IU/l
6) total bilirubin <=1.5mg/dl
7) serum creatinine <=1.50mg/dl
8) normal ECG
9. Written informed consent

Key exclusion criteria

1. Administration of the blood transfusion or G-CSF within 7 days before registration
2. History of serious drug hypersensitivity
3. Active infection
4. Watery diarrhea
5. Uncontrolled ileus
6. Active gastrointestinal bleeding
7. Severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema or etc)
8. Symptomatic brain metastasis
9. Active synchronous or metachronous malignancy, excepting for esophageal and gastric carcinoma
10. Severe abnormality of ECG, severe heart disease (congestive heart failure, symptomatic ischemic heart disease, uncontrolled arrhythmia, history of myocardial infarction within 12 months, or etc)
11. Severe mental disorders, neurological disease
12. Pregnant or lactation women, or women with the possibility of the pregnancy and men who want let to pregnancy
13. Patients who are judged inappropriate for the entry into this study by the investigator

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Wasaburo Koizumi

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code


Address

2-1-1, Asamizodai, Sagamihara, Kanagawa, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code


Address

2-1-1, Asamizodai, Sagamihara, Kanagawa, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Kitasato University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kitasato University School of Medicine, Department of Gastroenterology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 06 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 04 Month 03 Day

Date of IRB


Anticipated trial start date

2009 Year 04 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 06 Month 03 Day

Last modified on

2015 Year 04 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002486


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name